Literature DB >> 34725231

PSMA Expression Assessed by PET Imaging Is a Required Biomarker for Selecting Patients for Any PSMA-Targeted Therapy.

Jeremie Calais1, Johannes Czernin1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34725231      PMCID： PMC8612346          DOI： 10.2967/jnumed.121.263159

Source DB:  PubMed          Journal:  J Nucl Med        ISSN： 0161-5505            Impact factor:   11.082


× No keyword cloud information.
  16 in total

1.  [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.

Authors:  Michael S Hofman; Louise Emmett; Shahneen Sandhu; Amir Iravani; Anthony M Joshua; Jeffrey C Goh; David A Pattison; Thean Hsiang Tan; Ian D Kirkwood; Siobhan Ng; Roslyn J Francis; Craig Gedye; Natalie K Rutherford; Andrew Weickhardt; Andrew M Scott; Sze-Ting Lee; Edmond M Kwan; Arun A Azad; Shakher Ramdave; Andrew D Redfern; William Macdonald; Alex Guminski; Edward Hsiao; Wei Chua; Peter Lin; Alison Y Zhang; Margaret M McJannett; Martin R Stockler; John A Violet; Scott G Williams; Andrew J Martin; Ian D Davis
Journal:  Lancet       Date:  2021-02-11       Impact factor: 79.321

Review 2.  Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases.

Authors:  S D Sweat; A Pacelli; G P Murphy; D G Bostwick
Journal:  Urology       Date:  1998-10       Impact factor: 2.649

3.  Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617.

Authors:  Justin Ferdinandus; John Violet; Shahneen Sandhu; Rodney J Hicks; Aravind S Ravi Kumar; Amir Iravani; Grace Kong; Tim Akhurst; Sue Ping Thang; Declan G Murphy; Scott Williams; Michael S Hofman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-03-05       Impact factor: 9.236

4.  Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes.

Authors:  John Violet; Price Jackson; Justin Ferdinandus; Shahneen Sandhu; Tim Akhurst; Amir Iravani; Grace Kong; Aravind Ravi Kumar; Sue Ping Thang; Peter Eu; Mark Scalzo; Declan Murphy; Scott Williams; Rodney J Hicks; Michael S Hofman
Journal:  J Nucl Med       Date:  2018-10-05       Impact factor: 10.057

5.  Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study.

Authors:  Andrei Gafita; Jeremie Calais; Tristan R Grogan; Boris Hadaschik; Hui Wang; Manuel Weber; Shahneen Sandhu; Clemens Kratochwil; Rouzbeh Esfandiari; Robert Tauber; Anna Zeldin; Hendrik Rathke; Wesley R Armstrong; Andrew Robertson; Pan Thin; Calogero D'Alessandria; Matthew B Rettig; Ebrahim S Delpassand; Uwe Haberkorn; David Elashoff; Ken Herrmann; Johannes Czernin; Michael S Hofman; Wolfgang P Fendler; Matthias Eiber
Journal:  Lancet Oncol       Date:  2021-07-08       Impact factor: 41.316

6.  Investigating PSMA-Targeted Radioligand Therapy Efficacy as a Function of Cellular PSMA Levels and Intratumoral PSMA Heterogeneity.

Authors:  Kyle Current; Catherine Meyer; Clara E Magyar; Christine E Mona; Joel Almajano; Roger Slavik; Andreea D Stuparu; Chloe Cheng; David W Dawson; Caius G Radu; Johannes Czernin; Katharina Lueckerath
Journal:  Clin Cancer Res       Date:  2020-01-13       Impact factor: 12.531

7.  Imaging expression of prostate-specific membrane antigen and response to PSMA-targeted β-emitting radionuclide therapies in metastatic castration-resistant prostate cancer.

Authors:  Panagiotis J Vlachostergios; Muhammad Junaid Niaz; Myrto Skafida; Seyed Ali Mosallaie; Charlene Thomas; Paul J Christos; Joseph R Osborne; Ana M Molina; David M Nanus; Neil Harrison Bander; Scott T Tagawa
Journal:  Prostate       Date:  2021-01-19       Impact factor: 4.104

8.  Analysis of PSMA expression and outcome in patients with advanced Prostate Cancer receiving 177Lu-PSMA-617 Radioligand Therapy.

Authors:  Robert Seifert; Konstantin Seitzer; Ken Herrmann; Katharina Kessel; Michael Schäfers; Jens Kleesiek; Matthias Weckesser; Martin Boegemann; Kambiz Rahbar
Journal:  Theranostics       Date:  2020-06-19       Impact factor: 11.556

9.  Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy.

Authors:  Kerstin Michalski; Juri Ruf; Christian Goetz; Anna Katharina Seitz; Andreas K Buck; Constantin Lapa; Philipp E Hartrampf
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-12-18       Impact factor: 9.236

10.  What's behind 68Ga-PSMA-11 uptake in primary prostate cancer PET? Investigation of histopathological parameters and immunohistochemical PSMA expression patterns.

Authors:  Jan H Rüschoff; Daniela A Ferraro; Irene A Burger; Niels J Rupp; Urs J Muehlematter; Riccardo Laudicella; Thomas Hermanns; Ann-Katrin Rodewald; Holger Moch; Daniel Eberli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-08-13       Impact factor: 9.236
View more
  3 in total

1.  The VISION Forward: Recognition and Implication of PSMA-/18F-FDG+ mCRPC.

Authors:  Hossein Jadvar
Journal:  J Nucl Med       Date:  2021-12-21       Impact factor: 11.082

Review 2.  Current role of prostate-specific membrane antigen-based imaging and radioligand therapy in castration-resistant prostate cancer.

Authors:  Jiaxian Chen; Lin Qi; Yongxiang Tang; Guyu Tang; Yu Gan; Yi Cai
Journal:  Front Cell Dev Biol       Date:  2022-08-12

Review 3.  Radiolabeled PSMA Inhibitors.

Authors:  Oliver C Neels; Klaus Kopka; Christos Liolios; Ali Afshar-Oromieh
Journal:  Cancers (Basel)       Date:  2021-12-13       Impact factor: 6.639
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.